Publication Name	World Journal of Clinical Oncology
Manuscript ID	67608
Country	Spain

Received	2021-04-28 08:20
Peer-Review Started	2021-04-28 08:23
To Make the First Decision
Return for Revision	2021-07-16 05:51
Revised	2021-07-28 17:09
Second Decision	2021-11-22 03:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-11-25 02:49
Articles in Press	2021-11-25 02:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-12-02 01:30
Publish the Manuscript Online	2021-12-24 09:38

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
Manuscript Source	Invited Manuscript
All Author List	María Sereno, Oliver Higuera, Patricia Cruz Castellanos, Sandra Falagan, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes and Felipe Couñago
ORCID	Author(s) ORCID Number María Sereno http://orcid.org/0000-0002-0207-2118 Oliver Higuera http://orcid.org/0000-0002-6807-4511 Patricia Cruz Castellanos http://orcid.org/0000-0002-9837-825X Sandra Falagan http://orcid.org/0000-0001-7172-8873 Xabier Mielgo-Rubio http://orcid.org/0000-0002-0985-6150 Juan Carlos Trujillo-Reyes http://orcid.org/0000-0002-3370-0869 Felipe Couñago http://orcid.org/0000-0001-7233-0234
Funding Agency and Grant Number
Corresponding Author	María Sereno, MD, PhD, Consultant Physician-Scientist, Medical Oncology Department, Hospital Universitario Infanta Sofía, Paseo Europa 34, ES-28702 Madrid, Spain, San Sebastián de los Reyes 28702, Madrid, Spain. mariasereno75@gmail.com
Key Words	Immunotherapy combinations; Anti- programmed cell death protein; Anti-programmed cell death ligand 1; anti-TIGIT; anti-CTLA-4; Combo; Non-small cell lung cancer
Core Tip	This review presents the results of the main articles reporting on immunotherapy combinations, with or without chemotherapy, focusing principally on efficacy and toxicity data. The convenience of adding shorter chemotherapy regimens vs the standard 4-cycle regimens to immunotherapy doublets is discussed.
Publish Date	2021-12-24 09:38
Citation	Sereno M, Higuera O, Cruz Castellanos P, Falagan S, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer. World J Clin Oncol 2021; 12(12): 1182-1192
URL	https://www.wjgnet.com/2218-4333/full/v12/i12/1182.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i12.1182

Full Article (PDF)	WJCO-12-1182.pdf
Full Article (Word)	WJCO-12-1182.docx
Manuscript File	67608_Auto_Edited-A.docx
Answering Reviewers	67608-Answering reviewers.pdf
Audio Core Tip	67608-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	67608-Conflict-of-interest statement.pdf
Copyright License Agreement	67608-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	67608-Language certificate.pdf
Peer-review Report	67608-Peer-review(s).pdf
Scientific Misconduct Check	67608-Bing-Liu M-2.png
Scientific Editor Work List	67608-Scientific editor work list.pdf